scispace - formally typeset
W

Wendy Newcomer

Researcher at Johns Hopkins University

Publications -  5
Citations -  409

Wendy Newcomer is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Haemophilus influenzae & Vaccination. The author has an hindex of 5, co-authored 5 publications receiving 404 citations.

Papers
More filters
Journal ArticleDOI

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

TL;DR: A conjugate vaccine that links the H. influenzae type b capsular polysaccharide to the outer-membrane protein complex (OMPC) of Neisseria meningitidis serogroup B, administered at 2 and 4 months of age, is safe and induces a high rate of protection against invasive disease caused by H. Influenzaetype b in infants under the age of 18 months.
Journal ArticleDOI

Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children.

TL;DR: The effect of Haemophilus influenzae type b (H Hib) meningococcal protein conjugale vaccine (Hib-OMPC; Merck, Sharp & Dohme) on oropharyngeal (OP) carriage of Hib was evaluated in Navajo and Apache Indian children, who are known to be at high risk for invasive Hib disease.
Journal ArticleDOI

Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.

TL;DR: The HAV vaccine was well-tolerated and there were no serious adverse reactions; no vaccinee developed hepatitis A and further field studies are indicated to evaluate its use in high risk populations, such as the Navajo.
Journal ArticleDOI

Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine.

TL;DR: It is concluded that HbOC vaccine produced a significantly greater booster response than PRP-OMP vaccine when given at 12 to 15 months of age to children primed with two doses of PRP (PedvaxHib) vaccine.